Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2957 - Brain metastases in NSCLC patients in the era of precision medicine


09 Oct 2016


Poster display


Sheila Mpima


Annals of Oncology (2016) 27 (6): 103-113. 10.1093/annonc/mdw367


S. Mpima1, C. Anger2, L. Mitrofan3

Author affiliations

  • 1 Global Oncology, IMS Health, N1 9JY - London/GB
  • 2 Global Oncology, IMS Health, London/GB
  • 3 Global Oncology, IMS Health, 92088 - La Defence/FR


Abstract 2957


The frequent occurrence of brain metastases (BM) in patients with advanced NSCLC represents a significant obstacle to long-term survival. The development of targeted therapies (TTs) in NSCLC along with compelling evidence suggesting that EGFR overexpansion might play a role in cancer metastasis mechanism to the brain makes their usage a very appealing substitution approach to available treatment options in neurooncology. However, the literature describing effects of TTs on brain lesions and microenvironment remains sparse. In addition, initial clinical developments of systemic treatments in NSCLC exclude patients with active BM. Using real world data, we are able to profile patients with BM from NSCLC including full molecular profile along with the effects of the EGFR Inhibitors.


This study used IMS Oncology Analyzer™, a syndicated, retrospective, longitudinal cancer treatment database, collecting anonymized patient-level oncology data in EU5, projected to national level. Data collected between 2006 - 2015 was used to profile BM patients and treatment effects with a special emphasis on anti EGFR therapies.


Of the currently 607,437 treated population with BM, lung cancer accounts for 50%, followed by breast (14%), and melanoma (11%). NSCLC alone accounts for 34% from the entire currently treated population. 77% of the NSCLC with BM is non-squamous and 11% is EGFR mutated; mode age is between 61-65 years. 69 % of the studied population previously treated with EGFR inhibitors [erlotinib (ERL), gefitinib (GFT)], discontinued their therapy due to distant and/or local progression after on average 6.3 months while in patients with no BM it was on average 7.1 months. 10% of these patients were retreated with an EGFR inhibitor, either reversible (ERL, GFT) or irreversible (afatinib-based regimens, osimertinib). The remaining, received pemetrexed (28%), platinum-based therapies (9%), and chemotherapy alone (50%).


The usage of reversible EGFR inhibitors in BM patients from NSCLC has limited benefit and chemotherapy remains the treatment of choice after TTs failure. TTs which can penetrate the Blood-Brain Barrier today offer a new treatment option for BM patients, but further stratification of this patient segment is mandatory to drive clinical innovation.

Clinical trial identification

Legal entity responsible for the study

IMS Health


IMS Health


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings